menu
    • menu

    Company profile for XyloCor Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, i...
    XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    XyloCor TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1200 Liberty Ridge Drive, Suite 120 Wayne, PA 19087
    Telephone
    Telephone
    888-290-0081
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://xylocor.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/xylocor-therapeutics-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XyloCor Therapeutics Dose First Patient in Phase 2b EXACT-2 Trial
    XyloCor Therapeutics Dose First Patient in Phase 2b EXACT-2 Trial

    10 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250710062216/en/First-Patient-Dosed-in-XyloCor-Therapeutics-Phase-2b-EXACT-2-Trial-Evaluating-XC001-for-the-Treatment-of-Coronary-Artery-Disease

    BUSINESSWIRE
    10 Jul 2025
    Share Share
    XyloCor Raises $67.5M For Gene Therapy In Cardiovascular Disease
    XyloCor Raises $67.5M For Gene Therapy In Cardiovascular Disease

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107904126/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    XyloCor Therapeutics, SmartWise Enter License Agreement for Use of Extroducer
    XyloCor Therapeutics, SmartWise Enter License Agreement for Use of Extroducer

    10 Jul 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-07-10/xylocor-therapeutics-smartwise-enter-license-agreement-for-use-of-extroducer/?widget=listSection

    CONTRACT PHARMA
    10 Jul 2024
    Share Share
    XyloCor Licenses Extroducer From SmartCella For XC001 Heart Delivery
    XyloCor Licenses Extroducer From SmartCella For XC001 Heart Delivery

    10 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xylocor-and-smartcella-enter-into-license-agreement-for-use-of-the-extroducer-to-administer-novel-gene-therapy-xc001-to-the-heart-302193539.html

    PR NEWSWIRE
    10 Jul 2024
    Share Share
    XyloCor's XC001 Positive EXACT Phase 2 Data Presented, Published
    XyloCor's XC001 Positive EXACT Phase 2 Data Presented, Published

    02 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240501532555/en

    BUSINESSWIRE
    02 May 2024
    Share Share
    XyloCor Presents Phase 2 Data Highlighting Safety and Efficacy of XC001
    XyloCor Presents Phase 2 Data Highlighting Safety and Efficacy of XC001

    25 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230824534961/en

    BUSINESSWIRE
    25 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search